Abstract:The crystal structure of the title compound, [Ni(C(3)H(4)N(2))(6)][Ni(C(3)H(4)N(2))(3)(H(2)O)(3)](C(12)H(6)O(4))(2), contains uncoordinated naphthalene-dicarboxyl-ate dianions and two kinds of Ni(II) complex cations, both assuming distorted octa-hedral geometries. One Ni(II) ion is located on an inversion center and is coordinated by six imidazole mol-ecules, while the other Ni(II) ion is located on a twofold rotation axis and is coordinated by three water mol-ecules and three imidazole mol-ecules in a mer-NiN(3)O(3) arrangement. The naphthalene-dicarboxyl-ate dianion links both Ni(II) complex cations via O-H⋯O and N-H⋯O hydrogen bonding, but no π-π stacking is observed between aromatic rings in the crystal structure. One imidazole ligand is equally disordered over two sites about a twofold rotation axis; one N atom and one water O atom have site symmetry 2.

1-Naphthaleneacetic acid–piperidine (2/1)

Naphthalene-2,6-dicarboxylic acid&#8211;1-methylpyrrolidin-2-one (1/2)

Naphthalene-2,6-dicarboxylic Acid–1-Methylpyrrolidin-2-one (1/2)

Benzene-1,4-Dicarboxylic Acid-N,N-Dimethylacetamide (1/2)

Benzene-1,4-dicarboxylic acid&#8211;N,N-dimethylacetamide (1/2)

N-(2,4-Dinitrophenyl)dehydroabietylamine

1-Dehydroabietyl-4,5-diphenyl-1h-imidazole

Pyrrolidin-1-ium 2-(naphthalen-1-yl)acetate&#8211;2-(naphthalen-1-yl)acetic acid (1/1)

Hexakis(1H-imidazole-κN)nickel(II) Triaqua-Tris(1h-imidazole-κn)nickel(ii) Bis-(Naphthalene-1,4-dicarboxyl-ate).

Pyrrolidin-1-Ium 2-(Naphthalen-1-yl)acetate-2-(naphthalen-1-yl)acetic Acid (1/1)

Crystal Structure of Bis(1-Benzoylacetone)-p-naphthalenediimine, C30H26N2O2

(1,1′-Binaphthyl-2,2′-dioxy)diacetic acid

(Anthracen-9-yl)(piperidin-1-yl)methanone

Crystal Structure of the 1:2:2 Adduct of Piperazine, o -Phthalic Acid and Water

2-(4-Fluoro-phen-oxy)-N-methyl-acetamide

4-(9-Acridin-9-Ylamino)-2,2,6,6-Tetramethyl-Piperidine N-Oxide

Μ-Piperidine-κ2n:N′-bis[(3-nitrobenzoato-κo)silver(i)] Monohydrate

4,4-Diacetylheptanedinitrile

Crystal structure, Hirshfeld surface analysis, DFT optimized mol-ecular structure and the mol-ecular docking studies of 1-[2-(cyano-sulfan-yl)acet-yl]-3-methyl-2,6-bis-(4-methyl-phen-yl)piperidin-4-one

N,N′-Bis(2,6-diethylphenyl)acenaphthylene-1,2-diimine

μ-Piperidine-κ 2N:N′-bis[(3-nitrobenzoato-κO)-silver(I)] monohydrate